Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease

Journal of Immunology

Volumn 185, Issue 2, 2010, Pages 1230-1237

  Chung, Young C ^a,b   Kim, Sang R ^a,c   Jin, Byung K ^b  

^a Ajou University School of Medicine   (South Korea)

^b Kyung Hee University Hospital   (South Korea)

^c New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; PAROXETINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TUMOR NECROSIS FACTOR ALPHA; ANTIDEPRESSANT AGENT; DOPAMINE; PEROXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN NERVE CELL; CELL SURVIVAL; DNA DAMAGE; DRUG INHIBITION; ENCEPHALITIS; IMMUNOHISTOCHEMISTRY; MOUSE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; BRAIN; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVATION; GENETICS; INFLAMMATION; MALE; METABOLISM; MOTOR ACTIVITY; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BLOTTING, WESTERN; BRAIN; DOPAMINE; ENZYME ACTIVATION; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTERLEUKIN-1BETA; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; NADPH OXIDASE; NEURONS; NITRIC OXIDE SYNTHASE TYPE II; OXIDATIVE STRESS; PARKINSON DISEASE, SECONDARY; PAROXETINE; PEROXIDASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SUBSTANTIA NIGRA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77955504380     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1000208     Document Type: Article

References (53)

1. Dauer, W., and S. Przedborski. 2003. Parkinson's disease: mechanisms and models. Neuron 39: 889-909.
2. Olanow, C. W., and W. G. Tatton. 1999. Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci. 22: 123-144.
3. Savitt, J. M., V. L. Dawson, and T. M. Dawson. 2006. Diagnosis and treatment of Parkinson disease: molecules to medicine. J. Clin. Invest. 116: 1744-1754.
4. Hirsch, E. C., and S. Hunot. 2009. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol. 8: 382-397.
5. Choi, D. K., S. Pennathur, C. Perier, K. Tieu, P. Teismann, D. C. Wu, V. Jackson-Lewis, M. Vila, J. P. Vonsattel, J. W. Heinecke, and S. Przedborski. 2005. Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice. J. Neurosci. 25: 6594-6600.
6. Liberatore, G. T., V. Jackson-Lewis, S. Vukosavic, A. S. Mandir, M. Vila, W. G. McAuliffe, V. L. Dawson, T. M. Dawson, and S. Przedborski. 1999. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med. 5: 1403-1409.
7. Wu, D. C., P. Teismann, K. Tieu, M. Vila, V. Jackson-Lewis, H. Ischiropoulos, and S. Przedborski. 2003. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc. Natl. Acad. Sci. USA 100: 6145-6150.
8. Gao, H. M., B. Liu, W. Zhang, and J. S. Hong. 2003. Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease. FASEB J. 17: 1954-1956.
9. Moon, M., H. G. Kim, L. Hwang, J. H. Seo, S. Kim, S. Hwang, S. Kim, D. Lee, H. Chung, M. S. Oh, et al. 2009. Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease by blocking microglial activation. Neurotox. Res. 15: 332-347.
10. Anderson, I. M. 2000. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J. Affect. Disord. 58: 19-36.
11. Tom, T., and J. L. Cummings. 1998. Depression in Parkinson's disease. Pharmacological characteristics and treatment. Drugs Aging 12: 55-74.
12. Ceravolo, R., A. Nuti, A. Piccinni, G. Dell'Agnello, G. Bellini, G. Gambaccini, L. Dell'Osso, L. Murri, and U. Bonuccelli. 2000. Paroxetine in Parkinson's disease: effects on motor and depressive symptoms. Neurology 55: 1216-1218.
13. Tesei, S., A. Antonini, M. Canesi, A. Zecchinelli, C. B. Mariani, and G. Pezzoli. 2000. Tolerability of paroxetine in Parkinson's disease: a prospective study. Mov. Disord. 15: 986-989.
14. Lim, C. M., S. W. Kim, J. Y. Park, C. Kim, S. H. Yoon, and J. K. Lee. 2009. Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. J. Neurosci. Res. 87: 1037-1045.
15. Chavant, F., J. Deguil, S. Pain, I. Ingrand, S. Milin, B. Fauconneau, M. C. Pérault-Pochat, and C. Lafay-Chebassier. 2010. Imipramine, in part through tumor necrosis factor alpha inhibition, prevents cognitive decline and beta-amyloid accumulation in a mouse model of Alzheimer's disease. J. Pharmacol. Exp. Ther. 332: 505-514.
16. Taler, M., M. Bar, I. Korob, L. Lomnitski, E. Baharav, N. Grunbaum-Novak, A. Weizman, and I. Gil-Ad. 2008. Evidence for an inhibitory immunomodulatory effect of selected antidepressants on rat splenocytes: possible relevance to depression and hyperactive-immune disorders. Int. Immunopharmacol. 8: 526-533.
17. Jiang, J., T. Kuhara, R. Ueki, Y. Zheng, H. Suto, S. Ikeda, and H. Ogawa. 2007. Inhibitory effects of paroxetine on the development of atopic dermatitis-like lesions in NC/Nga mice. J. Dermatol. Sci. 47: 244-247.
18. Jackson-Lewis, V., and S. Przedborski. 2007. Protocol for the MPTP mouse model of Parkinson's disease. Nat. Protoc. 2: 141-151.
19. Kim, S. Y., K. C. Choi, M. S. Chang, M. H. Kim, S. Y. Kim, Y. S. Na, J. E. Lee, B. K. Jin, B. H. Lee, and J. H. Baik. 2006. The dopamine D2 receptor regulates the development of dopaminergic neurons via extracellular signal-regulated kinase and Nurr1 activation. J. Neurosci. 26: 4567-4576.
20. Kim, S. R., D. Y. Lee, E. S. Chung, U. T. Oh, S. U. Kim, and B. K. Jin. 2005. Transient receptor potential vanilloid subtype 1 mediates cell death of mesencephalic dopaminergic neurons in vivo and in vitro. J. Neurosci. 25: 662-671.
21. Paxinos, G., and K. Franklin. 2001. The Mouse Brain in Stereotaxic Coordinates. Academic Press, San Diego, CA.
22. West, M. J., L. Slomianka, and H. J. Gundersen. 1991. Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator. Anat. Rec. 231: 482-497.
23. Ferger, B., A. Leng, A.Mura, B. Hengerer, and J. Feldon. 2004. Genetic ablation of tumor necrosis factor-α (TNF-α) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum. J. Neurochem. 89: 822-833. (Pubitemid 38684730)
24. Ryu, M. Y., M. A. Lee, Y. H. Ahn, K. S. Kim, S. H. Yoon, E. Y. Snyder, K. G. Cho, and S. U. Kim. 2005. Brain transplantation of neural stem cells cotransduced with tyrosine hydroxylase and GTP cyclohydrolase 1 in Parkinsonian rats. Cell Transplant. 14: 193-202.
25. Choi, S. H., D. Y. Lee, E. S. Chung, Y. B. Hong, S. U. Kim, and B. K. Jin. 2005. Inhibition of thrombin-induced microglial activation and NADPH oxidase by minocycline protects dopaminergic neurons in the substantia nigra in vivo. J. Neurochem. 95: 1755-1765.
26. Park, K. W., and B. K. Jin. 2008. Thrombin-induced oxidative stress contributes to the death of hippocampal neurons: role of neuronal NADPH oxidase. J. Neurosci. Res. 86: 1053-1063.
27. Przedborski, S., V. Jackson-Lewis, R. Djaldetti, G. Liberatore, M. Vila, S. Vukosavic, and G. Almer. 2000. The parkinsonian toxin MPTP: action and mechanism. Restor. Neurol. Neurosci. 16: 135-142.
28. Giovanni, A., B. A. Sieber, R. E. Heikkila, and P. K. Sonsalla. 1991. Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine administration to several strains of mice. J. Pharmacol. Exp. Ther. 257: 691-697.
29. Block, M. L., L. Zecca, and J. S. Hong. 2007. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci. 8: 57-69.
30. Wu, D. C., V. Jackson-Lewis, M. Vila, K. Tieu, P. Teismann, C. Vadseth, D. K. Choi, H. Ischiropoulos, and S. Przedborski. 2002. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 22: 1763-1771.
31. Henkel, J. S., D. R. Beers, L. Siklós, and S. H. Appel. 2006. The chemokine MCP-1 and the dendritic and myeloid cells it attracts are increased in the mSOD1 mouse model of ALS. Mol. Cell. Neurosci. 31: 427-437.
32. Klevenyi, P., O. Andreassen, R. J. Ferrante, J. R. Schleicher, Jr., R. M. Friedlander, and M. F. Beal. 1999. Transgenic mice expressing a dominant negative mutant interleukin-1β converting enzyme show resistance to MPTP neurotoxicity. Neuroreport 10: 635-638.
33. Sriram, K., J. M. Matheson, S. A. Benkovic, D. B. Miller, M. I. Luster, and J. P. O'Callaghan. 2002. Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. FASEB J. 16: 1474-1476.
34. Zhou, C., Y. Huang, and S. Przedborski. 2008. Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance. Ann. N. Y. Acad. Sci. 1147: 93-104.
35. Babior, B. M. 1999. NADPH oxidase: an update. Blood 93: 1464-1476.
36. Cross, A. R., and A. W. Segal. 2004. The NADPH oxidase of professional phagocytes - prototype of the NOX electron transport chain systems. Biochim. Biophys. Acta 1657: 1-22.
37. Yamaguchi, H., K. Kajitani, Y. Dan, M. Furuichi, M. Ohno, K. Sakumi, D. Kang, and Y. Nakabeppu. 2006. MTH1, an oxidized purine nucleoside triphosphatase, protects the dopamine neurons from oxidative damage in nucleic acids caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Cell Death Differ. 13: 551-563.
38. Block, M. L., and J. S. Hong. 2005. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog. Neurobiol. 76: 77-98.
39. Miller, R. L., M. James-Kracke, G. Y. Sun, and A. Y. Sun. 2009. Oxidative and inflammatory pathways in Parkinson's disease. Neurochem. Res. 34: 55-65.
40. Oyagi, A., Y. Oida, H. Hara, H. Izuta, M. Shimazawa, N. Matsunaga, T. Adachi, and H. Hara. 2008. Protective effects of SUN N8075, a novel agent with antioxidant properties, in in vitro and in vivo models of Parkinson's disease. Brain Res. 1214: 169-176.
41. Seet, R. C., C. Y. Lee, E. C. Lim, J. J. Tan, A. M. Quek, W. L. Chong, W. F. Looi, S. H. Huang, H. Wang, Y. H. Chan, and B. Halliwell. 2009. Oxidative damage in Parkinson disease: measurement using accurate biomarkers. Free Radic. Biol, Med. 48: 560-566.
42. Aquilano, K., S. Baldelli, G. Rotilio, and M. R. Ciriolo. 2008. Role of nitric oxide synthases in Parkinson's disease: a review on the antioxidant and anti-inflammatory activity of polyphenols. Neurochem. Res. 33: 2416-2426.
43. Nagatsu, T., M. Mogi, H. Ichinose, and A. Togari. 2000. Cytokines in Parkinson's disease. J. Neural Transm. Suppl. (58):143-151.
44. Heneka, M. T., H. Wiesinger, L. Dumitrescu-Ozimek, P. Riederer, D. L. Feinstein, and T. Klockgether. 2001. Neuronal and glial coexpression of argininosuccinate synthetase and inducible nitric oxide synthase in Alzheimer disease. J. Neuropathol. Exp. Neurol. 60: 906-916.
45. Teismann, P., K. Tieu, O. Cohen, D. K. Choi, D. C. Wu, D. Marks, M. Vila, V. Jackson-Lewis, and S. Przedborski. 2003. Pathogenic role of glial cells in Parkinson's disease. Mov. Disord. 18: 121-129.
46. Zhao, C., Z. Ling, M. B. Newman, A. Bhatia, and P. M. Carvey. 2007. TNF-alpha knockout and minocycline treatment attenuates blood-brain barrier leakage in MPTP-treated mice. Neurobiol. Dis. 26: 36-46.
47. Oki, C., Y. Watanabe, H. Yokoyama, T. Shimoda, H. Kato, and T. Araki. 2008. Delayed treatment with arundic acid reduces the MPTP-induced neurotoxicity in mice. Cell. Mol. Neurobiol. 28: 417-430.
48. Bolin, L. M., I. Strycharska-Orczyk, R. Murray, J. W. Langston, and D. Di Monte. 2002. Increased vulnerability of dopaminergic neurons in MPTP-lesioned interleukin-6 deficient mice. J. Neurochem. 83: 167-175.
49. Hampton, M. B., A. J. Kettle, and C. C. Winterbourn. 1998. Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. Blood 92: 3007-3017.
50. Lau, D., H. Mollnau, J. P. Eiserich, B. A. Freeman, A. Daiber, U. M. Gehling, J. Brümmer, V. Rudolph, T. Münzel, T. Heitzer, et al. 2005. Myeloperoxidase mediates neutrophil activation by association with CD11b/CD18 integrins. Proc. Natl. Acad. Sci. USA 102: 431-436.
51. Petzinger, G. M., J. P. Walsh, G. Akopian, E. Hogg, A. Abernathy, P. Arevalo, P. Turnquist, M. Vucković, B. E. Fisher, D. M. Togasaki, and M. W. Jakowec. 2007. Effects of treadmill exercise on dopaminergic transmission in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury. J. Neurosci. 27: 5291-5300.
52. Jiménez-Jiménez, F. J., J. Tejeiro, G. Martínez- Junquera, F. Cabrera-Valdivia, J. Alarcón, and E. García-Albea. 1994. Parkinsonism exacerbated by paroxetine. Neurology 44: 2406.
53. Leo, R. J. 1996. Movement disorders associated with the serotonin selective reuptake inhibitors. J. Clin. Psychiatry 57: 449-454. (Pubitemid 26362308)